<?xml version="1.0"?><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:wgs84_pos="http://www.w3.org/2003/01/geo/wgs84_pos" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdaGr2="http://rdvocab.info/ElementsGr2" xmlns:oai="http://www.openarchives.org/OAI/2.0/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:dcterms="http://purl.org/dc/terms/"><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-69VGGJRZ/5791276c-2d1e-4d44-bc28-d641123510e9/PDF"><dcterms:extent>365 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-69VGGJRZ/65d7f676-0123-42d1-bc75-e723641a65db/TEXT"><dcterms:extent>18 KB</dcterms:extent></edm:WebResource><edm:TimeSpan rdf:about="2008-2025"><edm:begin xml:lang="en">2008</edm:begin><edm:end xml:lang="en">2025</edm:end></edm:TimeSpan><edm:ProvidedCHO rdf:about="URN:NBN:SI:doc-69VGGJRZ"><dcterms:isPartOf rdf:resource="https://www.dlib.si/details/URN:NBN:SI:spr-YR600LYC" /><dcterms:issued>2013</dcterms:issued><dc:creator>Dariš, Barbara</dc:creator><dc:creator>Hajdinjak, Tine</dc:creator><dc:creator>Kavalar, Rajko</dc:creator><dc:creator>Munda, Miha</dc:creator><dc:creator>Štiblar-Martinčič, Draga</dc:creator><dc:format xml:lang="sl">številka:1</dc:format><dc:format xml:lang="sl">letnik:6</dc:format><dc:format xml:lang="sl">str. 59-64</dc:format><dc:identifier>ISSN:1855-5640</dc:identifier><dc:identifier>COBISSID:4710463</dc:identifier><dc:identifier>URN:URN:NBN:SI:doc-69VGGJRZ</dc:identifier><dc:language>en</dc:language><dc:publisher xml:lang="sl">Medicinska fakulteta</dc:publisher><dcterms:isPartOf xml:lang="sl">Acta medico-biotechnica</dcterms:isPartOf><dc:subject xml:lang="sl">imunohistokemija</dc:subject><dc:subject xml:lang="sl">p53</dc:subject><dc:subject xml:lang="sl">prostata</dc:subject><dc:subject xml:lang="en">prostate</dc:subject><dc:subject xml:lang="sl">rak (medicina)</dc:subject><dc:subject xml:lang="sl">tkivni označevalci</dc:subject><dcterms:temporal rdf:resource="2008-2025" /><dc:title xml:lang="sl">Morphometrical analysis of the p53 tissue marker in prostatic adenocarcinoma and its relationship to Gleason score and PSA level| Morfometrična analiza tkivnega označevalca p53 v adenokarcinomu prostate v povezavi z oceno po Gleasonu in vrednostjo PSA|</dc:title><dc:description xml:lang="sl">Purpose: Prostate cancer is one of the most common malignancies worldwide. The possible prognostic value of tissue markers, such as p53, may give a better understanding of this disease, improve staging accuracy, and help in choosing optimal treatment. In this study, we examined p53 expression and its correlation with Gleason score, prostatespecific antigen (PSA) levels, and patient age in a Slovenian population. Methods: This retrospective pilot study included 25 radical prostatectomy patients. The immunohistochemical expression of p53 was determined and expressed as a p53 index. In addition, correlations between p53 index, Gleason score before and after prostatectomy, PSA level, and patient age were statistically evaluated. Results: The p53 tissue marker was unevenly distributed in prostate cancer independently of local Gleason pattern; however, its expression correlated with Gleason score after prostatectomy and showed borderline correlation with PSA. There were also statistically significant correlations between Gleason score before and after prostatectomy, PSA level, and patient age. Conclusions: Despite the low number of cases presented in this study, our results demonstrate that p53 may have predictive value in prostate cancer. Thus, p53 is a promising tissue marker that can be used as an additional diagnostic parameter</dc:description><dc:description xml:lang="sl">Namen: Rak prostate je v svetu zelo pogosta maligna bolezen. K natančnejši oceni bolezni bi lahko pripomogli tkivni označevalci, kot je na primer tudi p53. V vzorcih adenokarcinoma prostate slovenske populacje smo morfometrično analizirali izražanje p53 in njegovo povezavo z oceno po Gleasonu in vrednostjo PSA ter starostjo bolnikov. Metode: V retrospektivno pilotno študijo smo vključili 25 bolnikov z opravljeno radikalno prostatektomijo. Tkivni označevalec p53 smo določili imunohistokemično in ga izrazili kot indeks p53. Statistično smo poiskali povezave indeksa p53 z oceno po Gleasonu pred in po operaciji, vrednostjo PSA in starostjo bolnikov. Rezultati: Tkivni označevalec p53 je v raku prostate neenakomerno porazdeljen neodvisno od lokalnega Gleason vzorca, vendar korelira z oceno po Gleasonu po operaciji in mejno korelira z vrednostjo PSA. Statistično značilno so med seboj povezani tudi ocena po Gleasonu pred in po operaciji, vrednost PSA in starost bolnika. Zaključek: Potrdili smo, da ima p53 lahko napovedno vrednost kljub manjšemu številu primerov, vključenih v to raziskavo. Rezultati pilotne študije kažejo, da je p53 obetajoč tkivni označevalec in bi lahko bil uporaben kot dodatni diagnostični parameter</dc:description><edm:type>TEXT</edm:type><dc:type xml:lang="sl">znanstveno časopisje</dc:type><dc:type xml:lang="en">journals</dc:type><dc:type rdf:resource="http://www.wikidata.org/entity/Q361785" /></edm:ProvidedCHO><ore:Aggregation rdf:about="http://www.dlib.si/?URN=URN:NBN:SI:doc-69VGGJRZ"><edm:aggregatedCHO rdf:resource="URN:NBN:SI:doc-69VGGJRZ" /><edm:isShownBy rdf:resource="http://www.dlib.si/stream/URN:NBN:SI:doc-69VGGJRZ/5791276c-2d1e-4d44-bc28-d641123510e9/PDF" /><edm:rights rdf:resource="http://creativecommons.org/licenses/by/4.0/" /><edm:provider>Slovenian National E-content Aggregator</edm:provider><edm:intermediateProvider xml:lang="en">National and University Library of Slovenia</edm:intermediateProvider><edm:dataProvider xml:lang="sl">Univerza v Mariboru, Medicinska fakulteta</edm:dataProvider><edm:object rdf:resource="http://www.dlib.si/streamdb/URN:NBN:SI:doc-69VGGJRZ/maxi/edm" /><edm:isShownAt rdf:resource="http://www.dlib.si/details/URN:NBN:SI:doc-69VGGJRZ" /></ore:Aggregation></rdf:RDF>